Literature DB >> 11166826

Cyclin D1 by flow cytometry as a useful tool in the diagnosis of B-cell malignancies.

M O Elnenaei1, D M Jadayel, E Matutes, R Morilla, K Owusu-Ankomah, S Atkinson, I Titley, E M Mandala, D Catovsky.   

Abstract

The translocation (11;14)(q13;q32) and its molecular counterpart the BCL-1 rearrangement are features observed in mantle cell lymphoma (MCL) and less commonly in other B-cell disorders. This rearrangement leads to cyclin D1 overexpression, which may be the main pathogenic event in these tumours and is therefore recognised as a diagnostic marker. We developed a flow cytometry method to detect cyclin D1 overexpression using the monoclonal antibody (MoAb) 5D4, and characterised its frequency in 93 B-cell malignancies. The competitive reverse transcriptase polymerase chain reaction (RT-PCR) for cyclin D1, D2 and D3 was then performed on 40 of these cases to assess the validity of the flow cytometry method. Fluorescence in situ hybridisation (FISH) to detect t(11;14)(q13;q32) was carried out on 31 cases and results were compared with cyclin D1 expression by flow cytometry. Twenty five cases showed cyclin D1 expression using 5D4, including MCL (12/13, 92%), chronic lymphocytic leukaemia (CLL) (4/30), B-prolymphocytic leukaemia (B-PLL) (1/4), splenic lymphoma with villous lymphocytes (SLVL) (4/13), hairy cell leukaemia (HCL) (1/7) and other B-non Hodgkins Lymphoma (B-NHL) (3/15). There was a good correlation between flow cytometry results and RT-PCR in 36/40 cases (90%), and with FISH for t(11;14) in 25/31 cases (80%). We concluded that the detection of cyclin D1 expression by flow cytometry in cell suspensions could be applied routinely to the study of B-lymphoproliferative disorders and may be of value for their diagnosis and management.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11166826     DOI: 10.1016/s0145-2126(00)00114-4

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  8 in total

Review 1.  New additions to antibody panels in the characterisation of chronic lymphoproliferative disorders.

Authors:  E Matutes
Journal:  J Clin Pathol       Date:  2002-03       Impact factor: 3.411

2.  Detection of cyclin D1 in B cell lymphoproliferative disorders by flow cytometry.

Authors:  P Jain; G M Giustolisi; S Atkinson; M O Elnenaei; R Morilla; K Owusu-Ankomah; F Rafiq-Mohammed; E Matutes; A Wotherspoon; D Catovsky
Journal:  J Clin Pathol       Date:  2002-12       Impact factor: 3.411

3.  Mantle cell lymphoma presenting with paraproteinemia.

Authors:  Grzegorz Rymkiewicz; Monika Gos; Katarzyna Błachnio; Renata Woroniecka; Paweł Swoboda; Barbara Pieńkowska-Grela; Marika Kulińska; Anna Borawska; Przemysław Janik; Jan Walewski
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

4.  Quantitation of cyclin D1 over-expression using competitive fluorescent reverse transcription polymerase chain reaction: a tool for the differential diagnosis of mantle cell lymphoma.

Authors:  C L Wickham; H Armitage; M V Joyner; P Sarsfield; M Boyce; B S Wilkins; D B Jones; S Ellard
Journal:  Med Oncol       Date:  2003       Impact factor: 3.064

5.  Overlapping morphologic and immunophenotypic profiles in small B-cell lymphoma. A report of two cases.

Authors:  Ioannis Kostopoulos; Mario Cocco; Chiara Ginanneschi; Alessandro D'Amuri; Stefano Lazzi; Alberto Fabbri; Francesco Forconi; Maria Margherita De Santi; Lorenzo Leoncini
Journal:  Virchows Arch       Date:  2006-07-18       Impact factor: 4.064

6.  17Beta-estradiol affects the proliferation and apoptosis of rat bladder neck smooth muscle cells by modulating cell cycle transition and related proteins.

Authors:  Wafi Waladali; Yi Luo; Wen S Li; Min X Zheng; Quan L Hu
Journal:  World J Urol       Date:  2008-10-10       Impact factor: 4.226

7.  Expression of P-glycoprotein, Cyclin D1 and Ki-67 in Acute Lymphoblastic Leukemia: Relation with Induction Chemotherapy and Overall Survival.

Authors:  Ghada M Elsayed; Manar M Ismail; Manar M Moneer
Journal:  Indian J Hematol Blood Transfus       Date:  2011-06-21       Impact factor: 0.900

8.  Expanded clinical and experimental use of SOX11 - using a monoclonal antibody.

Authors:  Lena Nordström; Ulrika Andréasson; Mats Jerkeman; Michael Dictor; Carl Borrebaeck; Sara Ek
Journal:  BMC Cancer       Date:  2012-06-27       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.